Bevacizumab for Colorectal Cancer: 45 Real Stories

45 stories match colorectal cancer and bevacizumab. 41 of them mention targeted therapy.

Sydney, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Sydney Stoner: Stage IIIB to Stage IV colon cancer with liver and lung involvement

Patient Info: Sydney Stoner, Female, Under 40 | Stage IV

Metastatic Site: Liver; lungs

Progressed from Stage IIIB colon cancer to Stage IV disease involving the liver and lungs; treated with surgery/ileostomy/reversal, FOLFOX/FOLFIRI, lung radiation, liver ablation/resection, capecitabine, and ongoing Lonsurf + Avastin.

Fight Colorectal Cancer
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV colon cancer with a lung infection mimicking new metastases

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: KRAS wild-type; NRAS wild-type; BRAF wild-type; microsatellite stable; HER2-positive

Metastatic Site: liver

The colon primary and liver metastases achieved a partial response and were later assessed as stable with continued shrinkage. New lung nodules regressed with fluconazole, supporting pulmonary cryptococcosis rather than new cancer spread.

PubMed Central
OutcomeStable Disease
Adrienne, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV Colorectal Adenocarcinoma: Adrienne's Patient Story

Patient Info: Adrienne, Female | Stage IV

Metastatic Site: Liver

As of June 2026, Adrienne had Stage IV colon adenocarcinoma with liver metastases, had experienced liver recurrence after intensive multimodal treatment, and was back on FOLFIRI plus Avastin.

The Patient Story
OutcomeSetback / Progression
Lee, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Lee's Patient Story

Patient Info: Lee, Male, 50s | Stage IV

Metastatic Site: Liver

Lee initially reached no evidence of disease after chemotherapy and right hemicolectomy, but the cancer recurred in the liver about 1 year later, requiring FOLFIRI and liver resection with major postoperative complications.

The Patient Story
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Rectal cancer that spread through the lungs: complete remission after BRAF-targeted therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: BRAF mutation; HER2-negative; microsatellite stable; no detectable KRAS or NRAS mutations

Metastatic Site: lungs (pulmonary lymphangitic carcinomatosis);…

After progression with recurrent lung metastases and a new pericardial effusion, she chose hospice care and died in February 2025, 19 months after diagnosis.

PubMed Central
OutcomeIn Memory
Jim, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

My STAGE 4 Colon Cancer was Revealed by a Routine Blood Test! (NO SYMPTOMS!)

Patient Info: Jim, Male, 40s | Stage IV

Metastatic Site: Liver; lungs

Stage IV colon cancer with liver and lung metastases responded strongly to FOLFIRINOX-based chemotherapy, with tumor reduction over 70%, no detectable lung cancer on testing, and ongoing maintenance chemotherapy for remaining liver disease.

The Patient Story
OutcomeResponding Well
A patient, who was diagnosed with Colorectal CancerColorectal Cancer

Colon cancer patient with insulin autoimmune syndrome after FOLFOX, bevacizumab, and omeprazole

Patient Info: Anonymized, Male, 70+

Biomarkers: No cancer biomarkers reported. Insulin autoimmune syndrome followed chemotherapy/omeprazole exposure.

As of November 2025, the rare insulin autoimmune syndrome episode had improved after glucose supplementation and prednisone acetate, with blood glucose returning to the normal range during postoperative colon cancer treatment.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV KRAS-mutant colorectal cancer with bilobar liver metastases: multimodality treatment and no evidence of disease

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: KRAS-mutated; BRAF wild-type; mismatch repair proficient

Metastatic Site: liver

After second liver resection, follow-up MRI at 8 weeks showed continued response at the SABR site and no recurrent disease; she was receiving adjuvant capecitabine and remained well.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Kidney complication after switching colorectal cancer chemotherapy regimens

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver

The cancer had worsening liver metastases when FTD/TPI began. After treatment was stopped, steroid therapy resolved edema within 1 month and proteinuria returned to baseline 2.5 months after admission; the later cancer course was not established.

PubMed Central
OutcomeIn Treatment
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV sigmoid colon cancer: recurrence after FOLFOX, hepatectomy, and colectomy

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: Mismatch repair proficient; microsatellite stable; KRAS wild-type; BRAF wild-type; CEA 3.8 ng/mL at diagnosis

Metastatic Site: liver, lung

As of September 2025, metastatic sigmoid colon cancer had recurred in the lungs and remnant liver after initial FOLFOX, hepatectomy, and colectomy, requiring FOLFIRI plus cetuximab.

PubMed Central
OutcomeSetback / Progression
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV transverse colon cancer with NTRK fusion: entrectinib response followed by fatal PTTM

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: RAS/BRAF wild type, low TMB. CEA and CA19-9 were elevated before entrectinib and fell with response.

Metastatic Site: peritoneum, greater omentum, pleura,…

He died 7 weeks after hospitalization from pulmonary tumor thrombotic microangiopathy causing severe pulmonary hypertension and right-heart failure, despite biochemical and ascites response to entrectinib.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic colorectal cancer during pregnancy: chemotherapy and liver metastases

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Mismatch-repair deficient; KRAS ; BRAF not detected; CEA 38 ug/L; Lynch syndrome family history

Metastatic Site: liver, porta hepatis lymph nodes, retroperitoneal…

After initial response to FOLFOX, she developed bowel obstruction after moving closer to family and died during that admission after conservative management.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic colon cancer: soft-tissue and adrenal metastases responding to FOLFIRI plus bevacizumab

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: KRAS codon 146 mutation; BRAF wild type. CK20 and Ki-67 supported colorectal metastasis; CEA/CA19-9 were elevated.

Metastatic Site: lungs; left arm/biceps soft tissue; right…

As of May 2025, metastatic colon cancer involving soft tissue, muscle, lung history, and right adrenal gland had regressed after 12 months of FOLFIRI plus bevacizumab, and the patient was alive 1 year after chemotherapy completion.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic rectal cancer responding well after intensive treatment despite severe chemotherapy complications

Patient Info: Anonymized, Male, 40s | Stage IV

Biomarkers: KRAS exon 4 mutation, BRAF wild-type, PD-L1 CPS 2

Metastatic Site: liver, lung

After more than 14 months of treatment, the primary rectal tumor and most lung metastases had been resected, liver lesions had largely regressed, and he was described as near NED while continuing maintenance capecitabine plus bevacizumab.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Metastatic Colorectal Cancer With NRG1 Fusion Controlled for Years With Afatinib

Patient Info: Anonymized, female, 40s | Stage IV

Biomarkers: MATN-NRG1 fusion; no KRAS alteration detected

Afatinib controlled her metastatic colorectal cancer for 136 weeks. After resection of the remaining target lesion in September 2022, she remained alive with no progression as of October 2024.

PubMed Central
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV cecum cancer with liver and ovarian metastases: ramucirumab-related nephrotic syndrome and glomerular microangiopathy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Cancer biomarkers were not reported. Kidney injury workup showed severe protein leakage and biopsy-proven glomerular microangiopathy.

Metastatic Site: liver, right ovary

The liver metastasis shrank after XELOX plus bevacizumab and metastatic liver/ovarian sites were resected, but ramucirumab-based second-line therapy was stopped after nephrotic syndrome and severe glomerular microangiopathy; blood pressure and proteinuria improved with telmisartan.

PubMed Central
OutcomeCare Ongoing
Nick, who was diagnosed with Stage IV Colorectal AdenocarcinomaColorectal Cancer

Stage IV Colorectal Adenocarcinoma: Nick's Patient Story

Patient Info: Nick Sprague, Male, 40s | Stage IV

Metastatic Site: distant lymph nodes in abdomen/near aorta and left…

As of July 2024, Nick was living with Stage IVA colon cancer and receiving Keytruda/pembrolizumab with fewer side effects than chemotherapy; no NED status had been reached.

The Patient Story
OutcomeLiving With Cancer
Jessica, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Jessica's Survivor Story

Patient Info: Jessica Dazzler, Female, Under 40 | Stage IV

Biomarkers: FoundationOne testing performed; exact mutation not stated

Metastatic Site: lungs, spine, rib

As of May 2024, Jessica said it took 3 years and 4 months to reach no evidence of disease after Stage IV colorectal cancer, though she remained anxious about future scans and possible circulating cancer.

The Patient Story
OutcomeCancer-Free / NED
Jason, who was diagnosed with Stage IV Colorectal CancerColorectal Cancer

Stage IV Colorectal Cancer: Jason's Patient Story

Patient Info: Jason Reese, Male, 40s | Stage IV

Metastatic Site: Liver

As of January 2024, Jason still had active Stage IV rectal cancer, but extensive liver metastases had decreased from innumerable lesions to very few visible on scans, and treatment planning continued.

The Patient Story
OutcomeResponding Well